RAC 6.80% $1.89 race oncology ltd

Ann: Uni of Newcastle Heart Protection Collaboration Extended, page-25

  1. 2,651 Posts.
    lightbulb Created with Sketch. 2768
    TIP: Always Read Announcements Carefully.

    Worthwhile giving this announcement another read. It was announced separately to the Dox and Carfilzomib cardio protect results and relates to a panel review of cardiotoxicity from anti-cancer drugs. Similar to the FTO 100+ cancer program, this will establish utility of Zantrene as anti-cancer and cardio protect.

    https://hotcopper.com.au/data/attachments/4935/4935551-35ec91093cd3bda609c4996fc14d95aa.jpg
    Link: ea0834e2612591ca672825bbce1dd782 (sharelinktechnologies.com)

    Cardiotoxicity Panel-Review Program:

    We know that DrT is keen on being methodical so would expect that the cardiotoxic drugs are reviewed in the following list. Some research suggests that most have a link to iron metabolism, ROS and ferroptosis. If any of these mechanisms are the key then it expands the cardio protect from merely Dox and Kyprolis to various other classes of drugs. Most which we already know Zantrene synergises with from an anti-cancer perspective.

    This is pure speculation given the MOA is not yet published but is the difference between one or two v. multiple cardio protect opportunities. Looking forward to the results.

    https://hotcopper.com.au/data/attachments/4935/4935573-6b9473d87a9e93321c3b1b8b9b236be9.jpg
    https://hotcopper.com.au/data/attachments/4935/4935575-aef957fb410d46553ceafa0dae13b85f.jpg
    https://hotcopper.com.au/data/attachments/4935/4935576-ad4cb90593b395e118b55f81ec85bb51.jpg
    Link: http://jlgh.org/Past-Issues/Volume-12---Issue-4/Cardio-Oncology.aspx

    When should we expect the results from the "Panel review for Cardio-Protection"?

    I guess this fall into Cardio Protect in-vitro / in-vivo so based on the December 2022 Program update it should be H1 (2023) subject to timelines. If primary market research is already underway wonder if this would just include Zantrene as a drop-in replacement of Dox or extent to other cardio protective combo's?

    https://hotcopper.com.au/data/attachments/4935/4935587-90454e040e26b19f02191def047ee265.jpg
    Link: 6eaf0f2dd1535fb79c8b06e182abd8c3 (sharelinktechnologies.com)

    If Pharma ask, what other cardio-toxic treatments does Zantrene protect against, hopefully the results of this program can answer the question. This can provide commercial benefits in a number of ways:

    1. Synergise with Pharma's existing pipeline.
    2. Retain competitive advantage over other Pharma's.
    3. Increase patient outcomes and quality of life.

    Sure there are more feel free to add!
    Last edited by Boffin99: 29/12/22
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.